PTC Therapeutics Stock Soars on Novartis Licensing Agreement
Shares of PTC Therapeutics surged Monday when the pharmaceutical firm announced it struck a nearly $2 billion license and ...
Novartis in up to $2.9 billion licensing deal for PTC Therapeutics Huntington's disease drug
Swiss drugmaker Novartis will pay up to $2.9 billion for PTC Therapeutics' promising experimental drug for a neurological ...
PTC Therapeutics Inks Licensing Pact With Novartis Worth Up To ~$3 Billion For Huntington's Program
On Monday, PTC Therapeutics, Inc. (NASDAQ:PTCT) signed an exclusive global license and collaboration agreement with Novartis ...
FierceBiotech2d
Novartis pays PTC $1B upfront for midphase Huntington's program, reestablishing itself in R&D race
Novartis is paying $1 billion upfront for global rights to PTC Therapeutics’ midphase Huntington's disease program, helping ...
PTC Therapeutics signs up to $2.9 billion licensing deal with Novartis
PTC Therapeutics has signed an up to $2.9 billion licensing deal with Novartis AG for the U.S. company's experimental drug ...
GlobalData on MSN1d
Novartis and PTC Therapeutics link to develop Huntington’s therapy
Novartis has entered a worldwide licensing and partnership agreement with PTC Therapeutics to develop PTC518, a potential ...
BioPharma Dive2d
Novartis wagers billions of dollars on PTC Huntington’s drug
At the center of a new licensing deal is an experimental medicine, PTC518, which is currently being tested in a roughly ...
BioSpace2d
Novartis Pays Up to $2.9B in Huntington’s Deal With PTC
Monday’s agreement comes days after PTC discontinued the development of another asset, utreloxastat, due to disappointing ...
biopharma-reporter1d
PTC Therapeutics boosted by Novartis rights deal for Huntington’s program
The potential $2.9 billion deal stands the New Jersey company in good stead after recent disappointing results in its ALS ...
PTC Therapeutics price target raised to $71 from $47 at UBS
UBS raised the firm’s price target on PTC Therapeutics (PTCT) to $71 from $47 and keeps a Buy rating on the shares. PTC Therapeutics on Monday announced a global licensing and collaboration agreement ...
PTC Therapeutics enters global license, collaboration agreement with Novartis
PTC Therapeutics (PTCT) announced the signing of an exclusive global license and collaboration agreement with Novartis Pharmaceuticals ...
FIRSTonline2d
Ptc Therapeutics: $2,9 billion deal with Novartis for new experimental drug, stock price booms +20%
Ptc Therapeutics soars on the stock market with a +20% thanks to the exclusive agreement with Novartis for the PTC518 program against Huntington's disease. Agreement worth over 2,9 billion dollars. Ag ...